HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--July 28, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX - News) is pleased to announce that the Company’s NicAlert(TM) product will be used in a large smoking cessation study in collaboration with g-Nostics Ltd. in the U.K. The program will involve approximately 1,200 patients and 36 pharmacies assessing the clinical and cost effectiveness of g-Nostics Ltd.'s innovative pharmacogenetic smoking intervention, when used in a primary care setting. NicAlert(TM) will be used both for the initial measurement of cotinine levels in the subjects and to validate smoking status throughout the program.
